The Technical Analyst
Arcus Biosciences Inc [RCUS]
Exchange: NYSE Sector: Healthcare Industry: Biotechnology
Arcus Biosciences Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
5.44% $16.09
America/New_York / 9 mai 2024 @ 14:42
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 463.43 mill |
| EPS: | -4.15 |
| P/E: | -3.88 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 90.95 mill |
| Avg Daily Volume: | 0.752 mill |
| RATING 2024-05-09 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -3.88 | sector: PE 15.43 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.10x |
| Company: PE -3.88 | industry: PE 40.47 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 15.22 - 17.02 ( +/- 5.59%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-27 | Jarrett Jennifer | Sell | 11 551 | Common Stock |
| 2024-03-18 | Jarrett Jennifer | Sell | 12 153 | Common Stock |
| 2024-03-18 | Jarrett Jennifer | Sell | 1 296 | Common Stock |
| 2024-02-26 | Jarrett Jennifer | Sell | 24 555 | Common Stock |
| 2024-02-27 | Jarrett Jennifer | Sell | 34 070 | Common Stock |
| INSIDER POWER |
|---|
| 95.54 |
| Last 100 transactions |
| Buy: 19 279 293 | Sell: 529 920 |
Forecast:
16:00 - $16.08
Live Trading Signals (every 1 min)
Forecast
1: 14:51 - $16.10
Forecast 2: 15:41 - $16.09
Forecast 3: 16:00 - $16.08
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $16.09 (5.44% ) |
| Volume | 0.423 mill |
| Avg. Vol. | 0.752 mill |
| % of Avg. Vol | 56.21 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For RCUS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
RCUS
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
Latest Press Releases
2024-05-02 16:05:00 - Press Release
Arcus Biosciences To Participate In The Bank Of America Healthcare Conference 2024
Hayward, calif.--(business wire)--arcus biosciences (nyse:rcus), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming bank of america healthcare conference in las vegas, nv. the fireside chat will take place on thursday, may 16th, 2024 at 10:00am pt. a live webcast of the fireside chat will be available by visiting.
2024-04-24 16:00:00 - Press Release
Arcus Biosciences To Present New Data From Phase 2 Studies Of Novel Immuno-oncology Combinations At The 2024 Asco Annual Meeting
Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced three accepted abstracts at the 2024 american society of clinical oncology (asco) annual meeting, which will be held may 31 – june 4, 2024. the selected abstracts presented in partnership with gilead sciences provide strong support for the companies' portfolio of.
2024-04-23 16:05:00 - Press Release
Arcus Biosciences To Host Conference Call To Discuss First-quarter 2024 Financial Results And Pipeline Update
Hayward, calif.--(business wire)--arcus biosciences (nyse:rcus), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will host a conference call and webcast on wednesday, may 8th, 2024 at 1:30 pm pt / 4:30 pm et to discuss details of the company's financial results and pipeline update for the quarter ended march 31st, 2024. investors interested in listening to the c.
2024-04-09 16:35:00 - Press Release
Arcus Biosciences Announces New Employment Inducement Grants
Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the compensation committee of the company's board of directors granted 12 new employees options to purchase a total of 45,000 shares of the company's common stock at an exercise price per share of $16.97, which was the closing price on april 8, 2024, and rest.
2024-03-26 16:35:00 - Press Release
Arcus Biosciences Announces New Employment Inducement Grants
Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the compensation committee of the company's board of directors granted four new employees options to purchase a total of 18,400 shares of the company's common stock at an exercise price per share of $16.47, which was the closing price on march 25, 2024, and r.
Latest News
2024-05-08 21:55:26 - Seeking Alpha
Arcus Biosciences, Inc. (RCUS) Q1 2024 Earnings Call Transcript
Arcus Biosciences, Inc. (NYSE:RCUS ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Pia Eaves - Vice President of Investor Relations & Strategy Terry Rosen - CEO Jennifer Jarrett - COO Bob Goeltz - CFO Dimitry Nuyten - CMO Juan Jaen - President Conference Call Participants Kaveri Pohlman - BTIG Peter Lawson - Barclays Ashiq Mubarack - Citi Jonathan Miller - Evercore ISI Jason Zemansky - Bank of America Jeff La Rosa - Leerink Partners Rosemary Li - Cantor Fitzgerald Operator Hello, all and welcome to Arcus Biosciences First Quarter 2024 Earnings Call. My name is Lydia, and I'll be your operator today.
2024-05-08 18:46:26 - Zacks Investment Research
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Tops Revenue Estimates
Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.97. This compares to loss of $1.09 per share a year ago.
2024-05-01 11:05:37 - Zacks Investment Research
Will Arcus Biosciences, Inc. (RCUS) Report Negative Earnings Next Week? What You Should Know
Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2024-04-23 16:05:00 - Business Wire
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will host a conference call and webcast on Wednesday, May 8th, 2024 at 1:30 PM PT / 4:30 PM ET to discuss details of the Company's financial results and pipeline update for the quarter ended March 31st, 2024. Investors interested in listening to the c.
2024-02-28 16:05:00 - Business Wire
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in the following upcoming investor conferences in March: Leerink Global Biopharma Conference 2024 Date: Monday, March 11th, 2024 at 4:00 p.m. ET Location: Miami Beach, FL Format: Fireside Chat Barclays 26th Annual Global Healthcare Co.
2024-02-22 10:56:13 - Zacks Investment Research
Wall Street Analysts Think Arcus Biosciences, Inc. (RCUS) Could Surge 151.61%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 151.6% in Arcus Biosciences, Inc. (RCUS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2024-02-22 02:08:03 - Seeking Alpha
Arcus Biosciences, Inc. (RCUS) Q4 2023 Earnings Call Transcript
2024-02-07 17:00:00 - Business Wire
Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2023 Financial Results and Pipeline Updates
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will host a conference call and webcast on Wednesday, February 21, 2024 at 2:00 PM PT / 5:00 PM ET to discuss pipeline updates and details of the Company's financial results for the quarter and year ended December 31st, 2023. Investors interested in l.
2024-01-29 18:20:52 - Reuters
Gilead Sciences raises stake in cancer-centric Arcus Biosciences to 33%
Gilead Sciences said on Monday it has raised its stake in Arcus Biosciences to 33% and expanded its presence in the drug developer's board to three, deepening their collaboration in developing cancer drugs.
2024-01-10 08:01:12 - Seeking Alpha
iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch
